A phase I–II study of rituximab, ifosfamide, mitoxantrone andetoposide (R-IME) for B cell non-Hodgkin’s lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT)Robin Joyce, David Avigan, Jean-Pierre Tétreault et al.|Annals of Oncology|2003Cited by 13
Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.Robin Joyce, David Avigan, C N Kraser et al.|PubMed|2001Cited by 5